Aspen Neuroscience, Inc., is a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), which aim to use patients’ own cells to restore neuronal function and modify disease progression. Founded in 2018, our cell technologies are based upon the scientific work of a top team of scientists from The Scripps Research Institute. In 2020, Aspen announced a $70 million Series A financing, and is currently focused on advancing its lead product (ANPD001) and support continued development of its pipeline.
Located in scenic Torrey Pines, Aspen features a culture in which employees are respected and rewarded for hard work, innovation, personal initiative, and collaboration. The leadership team is committed to attracting and retaining the highest caliber talent to develop meaningful therapies for patients in need.
Aspen Neuroscience provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type. This applies to all terms and conditions of employment. We are committed to creating an inclusive environment for all employees.